Associated Papers
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
George TJ et al.
Jco Precision Oncology, 2024
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Pavan A et al.
Translational Lung Cancer Research, 2021
33569305 (PubMed )
Supplement: tlcr-10-01-202-supplementary.pdf
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Pécuchet N et al.
Oncotarget, 2017
26625312 (PubMed )
Supplement: oncotarget-08-23831-s002.xls › Feuil1
Select a paper to view details